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 Abstract  
Introduction: New frontiers in nanomedicine are moving towards the research of new 
biomaterials. Apoferritin (APO), is a uniform regular self-assemblies nano-sized protein with 
excellent biocompatibility and a unique structure that affords it the ability to stabilize small 
active molecules in its inner core.  
Areas covered: APO can be loaded by applying a passive process (mainly used for ions and 
metals) or by a unique formulative approach based on disassemby/reassembly process. In this 
article, we aim to organize the experimental evidence provided by a number of studies on the 
loading, release and targeting. Attention is initially focused on the most investigated 
antineoplastic drug and contrast agents up to the most recent application in gene therapy. 
Expert opinion: Various preclinical studies have demonstrated that APO improved the 
potency and selectivity of some chemotherapeutics. However, in order to translate the use of 
APO into therapy, some issues must be solved, especially regarding the reproducibility of the 
loading protocol used, the optimization of nanocarrier characterization, detailed understanding 
of the final structure of loaded APO, and the real mechanism and timing of drug release.  
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Article highlights box  
• APO is a self-assembled molecule highly conserved in mammalian and with a high 
biocompatibility. 
• APO offers the possibility to guest within its inner core drugs of low molecular weight 
and positively charged. The mechanism of drug loading can follow passive 
absorption/penetration processes or pH-dependent disassembly/reassembly protocols.  
• Only a limited number of drugs (mainly chemotherapeutics containing metals or 
anthracycline) are successfully loaded into APO, showing promising results in 
preclinical animal models.  
• APO is characterized by long lifetime and innate affinity for tumor cells due to its 
ability to bind human TtR1 receptor, over-expressed on cells in rapid proliferation.  
• Modern biotechnological approaches lead to the production of recombinant protein 
able to link molecules (active and/or targeting agents) directly to the protein structure, 
thus improving the efficacy of loaded APO and expanding its applicability to different 
field of therapy. 
  
1. Introduction 
The production and the development of drug delivery systems (DDS), completely 
biocompatible, atoxic, and biodegradable is a challenging issue. Thus, modern nanomedicine 
focused its interest on alternative biomaterials as proteins.  
The nature offers different types of multimeric proteins able to self-assemble in protein shell 
surrounding a hollow interior cavity with shapes and structures within nanometer scale [1]. 
From a biological point of view, protein cages play numerous functions as the storage, 
protection and delivery of viral genomes, metal storage, and protein refolding.  
Their applicability as DDS depends on the technological formulative aspects as handy, 
reproducible, scalable methods of formulation and drug encapsulation as well as on the 
efficient purification process. 
In this contest, advanced competences in the field of biotechnology help a sustainable large-
scale production of proteins using cell factories, making this technology highly desirable and 
economically advantageous for different technological applications.  
One of the most investigated classes of proteins applicable in drug delivery is the ferritin 
superfamily and particularly Apoferritin (APO) [2,3]. In this review, starting from the 
analyses of the structure of APO, we focus on the mechanism of drug loading in APO cage 
and the versatility of this protein as DDS in therapy.  
 
2. Ferritin superfamily 
Ferritins are a superfamily of proteins which is highly conserved in eukaryotic organisms and 
ubiquity diffused in humans and other mammals, plants, fungi, and bacteria [4]. 
The role of ferritin is fundamental for life; it is the first protein involved in iron storage and 
seizure, thus playing a role of reservoir for metabolic iron.  
The crystal structures of many Ferritins were deeply characterized since the beginning of 
1990s by the combination of Transmission Electron Microscopy (TEM), small angle X ray 
scattering (SAXS) and proteomic techniques [4-7]. 
In spite of large variations in amino acid sequences from bacteria to humans, ferritins 
essentially show the same architecture. Focusing on mammalians, the ferritin’s protein cage 
(450-500 kDa) is composed of 24 polypeptide subunits, with different molecular weights [8] 
and with specific functions [9]. Heavy (H) units (molecular weight of 21 KDa) play a major 
role in iron oxidation while light (L) units (molecular of 19 KDa) are more involved in the 
efficient nucleation and mineralization of iron. Of note, H and L subunits are highly 
homologous, and they can form a spherical unit in any proportion [10]. 
The ratio between the two types of chain in Ferritin is different with respect to the species and 
the tissues [11 as in relation to physiological state, as the amount of H chains increases in 
inflammation and other pathological conditions in response to cytokine stimuli [12,13]. 
Moreover, as reported in the text below (Chapter 4.1), differences in the type of receptor-
binding are present between H/L Ferritin/Apoferritin as only H-Ferritin or H-Apoferritin are 
able to bind TtR1 receptors whereas L-Ferritin and L-Apoferritin bind SCARA5 receptors. 
The subunits self-assemble to form a spherical cage with outer diameter of 12 nm, a 2 nm 
thick protein shell and a internal cavity with diameter of 8 nm. Overall, the protein molecular 
mass is 450KDa and it is able to store up to 4500 Fe(III) atoms [4,14]. 
The inner and the outer space are connected by pores size of about 0.3-0.5 nm [15, 16]: 8 of 
these pores defined “3-fold channels” are hydrophilic and they lead iron to diffuse into (and 
out of) the core; the other 4 pores defined “4 fold channels” are hydrophobic and their 
function is still unclear [17,18].  
Finally, it is worth to consider that during the protein reassemblation, amino acidic content 
differs from inner to outer cavities. Generally, ferritin have a preponderance of acidic over 
basic residues with high level of non apolar groups thus the isoelettric point is generally in the 
range 4.5-5.5).  
The ferritin surface resulted highly reactive and some substances can bind to the apoferritin 
surface through hydrogen bonding (non-ionic molecules) or electrostatic interactions (ionic 
molecules) [19]. 
 
3. From Ferritin to APO the applicability as DDS 
As above described, from a physiologic point of view, ferritin can be described as Fe (III) 
reservoir. Aiming to exploit APO as DDS, the inner cavity should be free and able to 
accommodate the cargo, thus the resident iron has to be removed from the cavities. 
Demineralization of ferritin occurred by reductive dissolution and subsequent chelation of 
Fe(II) producing APO [20,21] which maintains the same features of Ferritin in terms of inner 
and outer structures.   
The octahedral scaffold of APO displays typical hydrophilic and hydrophobic channels 
connecting inner cavities to the external surface and which are proposed as the route for 
inward and outward of metals and other molecules (therapeutic agents such as imaging 
agents) [22].  
This mechanism of accumulation into the core [23] is named “passive loading”. Unless 
initially investigated, being a rapid and scalable loading process, it results often less efficient 
and not able to stabilize therapeutic molecules with large molecular weights, which result 
prevalently adsorbed on the surface. Therefore, deeper studies on strategies of improving drug 
loading with active loading, or at least by means of strong modification in the protocols of 
Ferritin assembly were conducted over the last 10 years. In this contest, a number of studies 
mostly aimed to elucidate the permeation mechanism of organic molecules into APO and the 
impact of chemico-physical characteristics on drug loading efficiency. As example, NMR 
relaxation techniques were employed to investigate the diffusion of molecules devoid of net 
charge and with 18-7500 Da MW (i.e. water, DMSO, glucose, maltose, maltotriose, 
maltoteraose, maltopentaose and polyethylene glycol) into the protein cavity [24]. The authors 
demonstrated that the channel structure is sufficiently flexible to allow the penetration of 
molecules even larger than their own size (3-4 Å), but with maximum dimensions typical of 
the maltose (Mw: 342 Da, corresponding to a diameter of 13 Å) [24]. 
Electron paramagnetic resonance spectroscopy analysis were employed to study the diffusion 
of small and differently charged nitroxide organic probes (7-9 Å of diameter) to the central 
cavity of the ferritin, showing that the diffusion inside the protein is not purely passive (not 
only linked to the concentration gradient between the inside and outside of the protein) but 
also strictly dependent on their respective charge and the polarity. Only positively charged 
probes penetrate into the protein through the 3-fold channels, while not polar molecules bind 
the hydrophobic regions of the protein only on in its outer surface [25,26].  
Aiming to extend the number of applications, the research moves through alternative methods 
to load drug and investigate the dynamic of disassembly and reassembly of the protein 
nanocage. 
Thanks to a large number of intra- and inter-subunit salt bridges and hydrogen bonds, the 
APO structure is known for its stability: i) over heating condition (up to 85°C) [27]; ii) 
amongst a wide pH range (3.40-10) [28]; iii) in presence of high ionic concentrations; iv) in 
presence of high concentrations of denaturing agents [29,30]. 
Even if highly stable to chemical and physical denaturants, the APO architecture can be 
disassembled in response to pH variation and then restored, almost completely, by returning 
the pH back to the “physiological” conditions (pH 7.4). A number of hypotheses to describe 
the structural changes during disassembly and reassembly of protein were proposed.  
One of the first theories hypothesized that APO remains stable in the range of pH 2.8-10.6. 
On the contrary, at lower pH (1.6-2.8) or higher pH (10.6-13.0), a drastic reduction of MW, 
which can be related to the presence disassembled subunits, occurs [31]. 
A still open question is related to the exact pH at which protein starts its disassembling 
process. Some authors suggest that a progressive process [32] takes place; this event consists 
of cleavage of non-covalent bonds as a consequence of a conformational rearrangement of the 
protein [30]. Along with the decrease of pH, the outer surface of APO becomes positively 
charged (due to the protonation of the carboxylic groups of amino acid), leading to the 
progressive loosing of subunits forming holes in the spherical structure which switch from the 
inside to the outside [31]. By combining SAXS data and 3D structural reconstruction, it was 
shown that more the pH decreases and more the holes become numerous and larger, finally 
generating rodlike structures at pH 2 [28]. 
In these conditions, APO is completely disassembled into its subunits and allows to 
molecules/drug present in solution to interact with the chains.  
To lead sub units to reassemble and to form the native conformation, it is pivotal to restore the 
native electrostatic potential, thus, the solution needs to be buffered to the pH to 
“physiological” values [33]. Within this reassembly process, drug loading takes places as the 
drug molecules are entrapped into the spherical structure (Fig.1).  
In turns, aiming to expand the drug loading possibilities, some authors chose to move to 
different pH values, especially in the basic range. Notwithstanding less conformational data 
are available regarding the basic dissociation of APO, it was supposed starting over pH 10.6 
and caused by the de-protonation and re-arrangement of tyrosine residues. A high level of 
attention should be posed on monitoring pH values, as continuing the basification over pH 
12.4 lead to an irreversible alkaline hydrolysis of peptide bonds [34], disabling any possible 
recovery of native conformation [31]. 
 
4. Pharmacokinetics of APO as DSS 
After parenteral administration the pharmacokinetic profile of APO was investigated in tumor 
bearing model. Drug-loaded APO are rapidly distributed into the bloodstream reaching small 
capillaries. These protein DDS do not cross normal vessels, as only molecule smaller than 3 
nm are allowed to pass the endothelial cells by means of transcellular route [35], but their low 
diameter (less than 20 nm) is sufficient to avoid macrophages capture. This drastically 
reduces a-specific uptake by the reticular endothelial system (RES) [36] and assures to keep 
the protein longer into bloodstream circulation.  
Membranes of endothelial cells of blood vessels expose receptors that recognize APO and 
control both iron uptake and transferrin passage from vessel to tissues. H and L subunits show 
some differences in receptor affinity, as the H subunit specifically binds the receptor of 
transferrin (TfR1) with a wild distribution in human cells while L subunit binds to the 
Scavenger Receptor Class A Member 5 (SCARA5) firstly localized in macrophages, retina 
and hepatocytes [10,37].  
As evident, the protein composition is pivotal to define the APO destiny and, at the same 
time, the well-known over-expression of TfR1 in many cancer cells (about 100-fold respect to 
normal tissue) [38,39] guarantees an intrinsic site-specific targeting potential of APO 
nanocage for tumor.  
Moreover, tumor produces much more growing factors, leading to the presence of blood 
capillaries which tend to be disorganized, oversized, and leaky. As consequence, a large 
number of drug molecules and small structure (as APO) can be effectively driven to cancer 
tissue and stick onto pathological cells.  
Also the mechanism of APO interaction with cells and especially with tumor cells was 
investigated, in vitro using CACO-2 cells, showing that APO exploits clathrin-dependent 
endocytosis [40], accumulates into endosomes and releases the protein cargo into cytoplasm 
as a consequence of acidification of the compartment, which is responsible of the progressive 
dissociation of APO [41].  
 
4.1 APO in drug delivery, the tumor case 
A number of anticancer drugs suffer poor selectivity for neoplastic cells leading to dose-
limiting side effects, which compromise clinical outcomes. 
.  
Unfortunately, only limited number of drugs were investigated as well-defined drug 
properties are needed: i) controlled molecular weight (typically in the range 300-600 Da); ii) 
positive charged at physiological pH thus able to produce electrostatic interaction with the 
inner negatively charged protein cavity. In this view, DOXO possesses good properties 
(MW= 544 Da; and pKa= 7.34 (phenol); 8.46 (amine); 9.46 (est). Different operative 
conditions were screened in order to optimize its loading into APO, in particular the effect of 
the buffer, the ionic strength and the protein concentration during the dissociation process.  
During the last decades, the major interest was dedicated to the investigation of the 
development of loaded APO as DDS for anticancer molecules (Table 1). Among current used 
chemioterapeutics with low bioavability and selectivity some of them display chemico-
physical characteristics (low MW and cationic charge at physiologic pH) suitable for 
stabilization into APO. Moreover, thanks to the innate affinity for tumor cells the 
encapsulation is supposed to enhance the cell interaction with the tumor cells thus reducing 
the side and not-target accumulation and side effects. Considering this particular cancer 
targeting, H-ferritin should be used in order to produce cages able to really and successfully 
target cancer human cells. Notably, mouse models of cancer should not be taken into 
consideration, due to the presence of different receptors. 
 
Gefinitinib, an epidermal grown factor (EGFR) receptor tyrosine kinase inhibitor (MW 447 
Da), was passively loaded in APO. Drug resulted probably distributed in the inner and outer 
part of the protein cage (totally 10 molecules for each APO), thus the release starts at 
physiological pH and maximizes at pH 2 in correspondence with the protein disassembly. 
Authors demonstrated that Gefinitinib/APO induced cytotoxicity in breast cancer cell lines 
over-expressing both TtR1 and HER-2 receptors whit a profile comparable to that of free drug 
[42].  
A strong effort in the research was focused on strategies to force structured molecules to 
stably enter the APO core. In some particular cases (i.e. doxorubicin and mainly Gd), for 
molecules with appropriate MWs, some authors proposed a pre-complexation of the molecule 
with a metal in order to use the natural affinity of metal for the inner core of APO as driving 
force to maximize the passage through the 3-fold channels.  
Doxorubicin (DOXO), a wide spectrum anticancer antibiotic with affinity for different metals 
was previously pre-complexed with Cu(II), and efficiently loaded by simple incubation in 
APO systems (Cu/DOXO/APO)[43,44]. These strategy increases the drug loading efficiency 
in APO compared by simple DOXO/APO (30:100 DOXO:APO w/w ratio in presence of Cu 
respect to 8:100 DOXO:APO w/w ratio in absence of metal) [45]. Cu/DOXO/APO keeps both 
the dimension and the morphology of DOXO/APO and APO alone and no aggregates were 
observed. The release of the drug in physiological conditions, showed a typical biphasic 
profile characterized by an initial bust effect (about 80% of drug) and absence of drug release 
over 48 h. These data could indicate that the metal-drug complex is mostly adsorbed on the 
surface of protein. Notwithstanding technological data seems to suggest only a limited ability 
to protect DOXO, in vitro and in vivo tests on tumor models showed that DOXO/APO 
nanocages, targeted to integrin Rvβ3 (a tumor angiogenesis biomarker) by RGD peptide 
anchored on APO surface, displayed a better therapeutic profile, resulting in a longer 
circulation half-life, higher tumor uptake, better tumor growth inhibition, and less 
cardiotoxicity than free DOXO [45]. 
A second strategy proposed to force the drug into the protein core consists of disassembly-
reassembly process. The natural metal binding site present in the inner core of APO can be 
used as driving force to stabilize some metal-containing compounds. In this contest, platinum 
based anticancer drugs could be efficiently encapsulated into APO after dissociation at pH 2 
and reconstitution at physiologic pH. 
Cisplatin and carboplatin were loaded with the aim to reduce the systemic toxicity and high 
tumor resistance [46]. Through ICP-MS analysis authors demonstrated that about 2 and 5 
molecules of cisplatin and carboplatin respectively became part of the protein structure, even 
if not clear evidences about the rate between internalization and absorption were reported. In a 
further study, these data were corroborated by a deeper characterization of platinum loaded 
APO (oxaliplatinum) and evaluating the effect on a cancer cell line overexpressing transferrin 
receptor. Data highlighted the low toxicity of APO on cancer cells and the rapid decreased of 
cellular viability as a consequence of internalization of loaded protein, thus suggesting the 
potentiality of APO to overcome the mechanism of resistance typical of this type of metal 
based anticancer drug [35]. 
As alternative, cisplatin was stabilized into APO after dissociation at more handy and “stable” 
formulative conditions, as weak alkaline pH [47]. Once tested on cancer cells cisplatin loaded 
into APO showed the ability to induce cytotoxicity through the same apoptosis pathway of 
free drug. Even if it is not clearly proved the exact localization of the drug within the APO, 
the evidence that APO slows down the biological response at short time respect to free drug, 
suggests that the protein plays an important role in controlling the drug release over the time. 
Disassembly-reassembly process was also applied to load drugs in APO without pre-
complexation with metal. To date, only limited number of drugs were investigated as well-
defined drug properties are needed: i) controlled molecular weight (typically in the range 300-
600 Da); ii) positive charged at physiological pH thus able to produce electrostatic interaction 
with the inner negatively charged protein cavity. In this view, DOXO possesses good 
properties (MW= 544 Da; and pKa= 7.34 (phenol); 8.46 (amine); 9.46 (est). Different 
operative conditions were screened in order to optimize its loading into APO, in particular the 
effect of the buffer, the ionic strength and the protein concentration during the dissociation 
process.  
Interestingly, the use of glycine-acetate buffer (pH 2.5) is the one more efficacious approach 
in disassembling APO without any effect related to the initial protein concentration [48].  
Since only H chain showed affinity for cancer cells through the binding with transferrin 
receptor, by means of an elegant combination of chemical engineering and fermentation 
technology, different types of mammalian ferritin variants were formulated by self-
assembling by only H subunits (H-APO) [49]. Thus, H-APO was loaded with DOXO 
following both the previously reported acidic [50,51] or basic dissociation protocols [52]. The 
complex DOXO loaded H-APO (DOXO/H-APO), tested in vitro, was compared in term of 
efficacy with free DOXO and with clinical approved liposome loaded DOXO formulation 
(Doxil®).  
The “innate” targeting ability of the protein cage was confirmed as DOXO/H-APO showed 
better ability to mediate efficient and rapid interactions with cancer cells than the other 
control formulations [50,51]. Some conflicting data derived from in vitro distribution studies; 
DOXO/H-APO rapidly entered in a colon cancer cell line accumulating in lysosomes where 
DOXO is gradually released and subsequently translocated into nucleus [52]. Differently, in a 
liver carcinoma cellular line, DOXO/H-APO accumulated rapidly into nucleus through a 
specific interaction of H subunit with receptor exposed on nuclear membrane. Accordingly, 
DOXO intercalates DNA causing higher and more rapid cytotoxicity in cancer cells respect to 
controls (DOXO or Doxil) [50-51].  
We could speculate on the different biological response and mechanism of cellular 
accumulation as consequence of multiple aspects, especially relating to the sensibility of 
tumor type and to the effect of the architecture and surface proprieties of loaded APO 
formulated applying different protocols. As evident, more efforts are needed to completely 
characterize these new entities. 
To go further, DOXO/H-APO, obtained by means of basic dissociation protocol, was in vivo 
tested aiming to investigate pharmacokinetics profile and toxicity in mice bearing tumor 
(colon cancer cells). Namely, DOXO loaded into APO showed 10 fold higher AUC and tumor 
accumulation with respect to free drug and Doxil and reduced the drug concentration in 
healthy tissues (muscle, lung, kidney, spleen and most importantly heart). In addition, 
DOXO/H-APO led to a significant reduction in tumor growth two-fold higher than Doxil® 
[52].  
The protocols for encapsulation of DOXO are now used as a template. Recently atropine and 
carbachol, two molecules active on muscarinic receptors, involved in the development of 
pancreatic tumor, was loaded into APO cage. All studied molecules show similar MW 
(carbachol=183 Da; atropine=290 Da) and pKa (carbachol=12.5; atropine=4.5), suggesting 
loading efficiencies similar to DOXO case. Authors described an efficient accumulation both 
in vitro and in vivo at the tumor site, a partial suppression of tumor development and a 
reduction of toxicity if compared with the treatment with free drugs [53]. 
To ameliorate the affinity of APO for cancer cells, some authors proposed the surface 
modification by the insertion of target moieties as antibodies or peptides.  
APO has a fair versatility regarding chemical reactivity: in fact, a variety of chemical groups, 
e.g. primary amines, carboxylates, and thiols present on the external and internal surface, can 
be linked either genetically [29,45] and/or chemically [54,55]. Interestingly, after surface 
modification, APO diameter generally increased and the surface proprieties change (zeta-
potential, hydrophilicity). As a consequence, the cellular interaction appeared to be more 
driven by the presence of ligands exposed onto the surface than by the “innate” tumor affinity 
of APO.  
That way, a complex of daunorubicin (DAUNO) with negatively charged polypeptide PLLA 
(poly-L-aspartic acid) [24,56] was incorporated into APO after a partial disassembling at pH 5 
and reassembly at physiological pH. To target solid tumor cells, the surface of APO was 
engineered (by means of NHS/EDC protocol) with hyaluronic acid able to specifically bind 
CD44. The efficacy of this engineered nanocage was in vitro tested on a lung cancer cells 
overexpressing CD44 and a control cell line, not expressing any antigen. Modified nanocages 
were safe and tolerable for both cell lines, but it was clearly demonstrated that the cellular 
uptake was strongly driven by the binding with the cellular antigen. Briefly, DAUNO/APO 
accumulated only in CD44 positive cell line and both the cellular uptake and cytotoxicity 
were sensible to the pre-incubation with free antigen (which means inhibiting the cell specific 
binding) [56]. 
In a second example, APO loaded with cisplatin proposed by Xing and collaborators [35] was 
conjugated through a NHS-PEG-Mal cross-linker with an antibody selective to a proteoglycan 
expressed on the surface of melanoma cells (CSPG4). The new modified vectors showed a 
significant increase in both their molar mass and diameters (33 nm Vs 13 nm of native APO). 
In vitro studies confirmed that modified APO specifically bound melanoma cells expressing 
CSPG4(+), but not CSPG4(-) breast cancer cells and, accordingly, in vivo study showed a 
delayed tumor growth in model mice of melanoma. On the contrary, the tumor size of breast 
tumor, which does not over-expressed the specific antigen, was only marginally affected [57].  
Recently APO was proposed as non-viral system to stabilize and protect small interfering 
RNA (siRNA). SiRNA are characterized by high MW and negatively charges, features that 
hampered a stable internalization into the protein core. Taking advantage of the protein 
recombinant technology, APO was modified aiming to orderly expose cationic peptides on its 
surface. Thus, protamine-derived peptides were inserted as moieties able to complex and 
capture siRNA; besides, APO was also modified with penetrating peptides to enhance the 
target delivery to tumor cells.  
The experiments clearly highlighted that after modified-APO/siRNA complexation, the 
targeting peptides exposed on the protein surface drove the complex-cellular interaction and 
siRNA accumulated into the cell cytoplasm, thus opening to a great potential for further 
applications of APO in gene therapy applied to cancer treatment (Fig. 2; Table 1) [58].  
 
 
4.2 Application of APO in diagnosis 
Imaging agents are among those compounds that can be successfully loaded into the interior 
cavity of APO protein (Table 2).  
Magnetic Resonance Imaging (MRI) is a non-invasive imaging method for tumor diagnosis, 
however most of the diagnostic agents suffers from a lack of selectivity, low proton relaxivity 
and higher toxicity after administration [59]. 
APO could act as dual-functional tools allowing both the use of protein shell to target tumors 
and the ability in loading probes within the internal core to image tumors. 
Gadolinium (GD) is one of the most used contrast agent in clinical and experimental settings; 
thus a number of authors proposed the formulation of water suspended APO-GD formulation 
with high NMR longitudinal relaxivity similar to clinically approved GD-chelates. [59-62]. 
The technology employed in order to stabilize this contrast agent, described for the first time 
more than 10 years ago, was based on a well-described acidic protocol (dissociation at pH 2) 
and the use of a neutral chelates (GD-HPDO3A) [59].  
To improve tumor targeting, the surface of APO/GD-HPDO3A was engineered via 
streptavidin-biotin technology with an antibody directed to neural cell adhesion molecules 
(NCAM), overexpressed during the angiogenesis in endothelial cells. After in vivo 
administration, this new contrast agent was stable for few hours with a relaxation efficiency 5-
fold higher with respect to the free probe, showing an increase in selectivity for tumor vessels 
[62]. 
In a more recent work, in order to maximize the loading efficiency, GD-HPDO3A was 
replaced with a positively charged GD-Me2-DO2A. With the aim to assure a stable insertion 
into the cavity, the process was modified by adding GD complex during the acidification 
stage (at pH 4). Finally, the surface decoration of GD loaded APO with dextran lead to the 
accumulation of APO in transplanted tumor region in mice due to the exploitation of EPR 
effect [60]. 
Also Mn ions could be used as contrast agent in MRI. Through the stabilization into APO it 
has been demonstrated the improving in relaxitivities [63, 64]. These non invasive imaging 
tools were applied as MRI sensor for different kinds of tumor. Taking advantage of the 
reduced expression of SCARA5 (ine of the APO cellular receptor) into hepatoma cells respect 
to health hepatocites, Geninatti and co-workers demonstrated the possibility to discriminate 
between tumor lesion and monitor the hepatic tumor progression with a sensitivity similar to 
commercial probe (Gd-BOTA) [65]. A similar structure was also developed for the early 
diagnoses and imaging of melanoma cells. The increased melanin production in cancer cells 
correspond to an increased reduction of Mn (III) to Mn (II) (by the oxidation of L-DOPA to 
melanin) thus producing an high relaxivities and contrast during MRI investigation [66]. 
Also iron is another optimal contrast agent for MRI. Autologous ferritins have been 
successfully investigated as a MRI contrast agent. One of the first example reported described 
the use of a cationized ferritins for MR imaging of kidneys (obtained after coupling with N, N 
dimethyl-1,3 propanediamine (DMPA) that after iv administration accumulated in the kidneys 
because the glomerular basement membrane is negatively charged [67]. More recently ferritin 
was investigated as MRI contrast agent in neurodegenerative disorders because of the 
documented alterated iron metabolism in many neurodegeneration (particularly Alzheimer’s 
disease and Huntington’s disease [68]. As example of this application in vivo experiments in 
mice demonstrated that it is possible to increase the iron expression (thus the MRI signal) in 
nerve cells of mice after transfection of nerve cells using lentiviral and adenovirus vectors 
expressing transferrin [69] (for a complete review on this point see ref. 70). Unless some 
application reported, generally endogenous ferritin shows low relativity index if compared to 
synthetic iron oxide nanoparticles [71]. Human recombinant H-APO offers the possibility to 
act as suitable platform for synthesis and encapsulation of magnetite nanoparticles (Fe3O4), 
leading to the obtainment of optimal contrast agent for MRI for tumor diagnoses. Starting 
from the first studies on APO formulation containing an iron core in the form of magnetite 
(Fe3O4) [72-73], the research moved to the surface engineering aiming to achieve improved 
tumor selectivity. That way, magnetoferritin was modified using ligand able to target tumor 
markers such as RGD-4C that can specifically target tumor angiogenesis via binding to 
integrin molecules on vascular endothelium [74] melanocyte-stimulating hormone (MSH), or 
epidermal growth factor (EGF) [75,76]. Besides the surface modification to increase the 
tumor detection, other imaging modalities, such as fluorescence imaging and positron 
emission tomography (PET) were investigated [77]. 
Recently, APO loaded with Cu64 and Cy5 was modified with RGD4C peptide anchored to 
the ferritin surface by conjugation with the surface amines. This structure was able to target 
the tumor, by means of RGD-integrin interaction and the enhanced permeability and retention 
(EPR) effect [78].  
 
 
4.3 Application of Apo as theranostic tool 
The growing knowledge and advances in nanomedicine drive the recent research in 
formulating systems containing simultaneously both drugs and imaging agents. The 
combination of therapy and diagnoses in a single drug delivery system is now emerging as 
theranostic approach.  
This strategy can find applications for various different purposes, as to monitor the 
biodistribution and the target site accumulation of nanomedicines, to visualize and quantify 
drug release, and to assess the efficacy of the therapeutic treatment [79,80]. 
The design of a theranostic nanosystems could be obtained by following different protocols in 
terms of drug loading processes and insertion of the diagnostic agents (Table 3).  
The DOXO/APO systems characterized by a natural affinity for tumor were largely studied 
and recently were modified onto their surface with magnetic particles by means of 
streptavidin-biotin technology. This approach preserved the natural loading ability of APO 
and it avoided any possible incompatibility between drug and diagnostic agent. Authors 
demonstrated that modified DOXO/APO was sensible to the application of a magnetic field, 
thus enabling also a pH-dependent release of the drug and opening the pave to a possible in 
vivo application in the treatment and diagnoses of tumors [54]. 
More recently a DOXO/APO complex was specifically designed as theranostic agent for 
prostate cancer. Briefly, the surface was double engineered with an antibody direct to anti 
PMSA (prostate specific membrane antigen) and with gold nanoparticles. The complex 
coverage of protein seems to protect the cargo from undesired premature release in the 
bloodstream; moreover, once tested in vitro, this new carrier assured a nice selectivity for 
prostate cancer cells preserving healthy cells from the drug toxicity [81]. 
A different approach is based on a contemporary loading into the inner cavity of the protein of 
diagnostic and drug molecules.  
The cytostatic drug 5-fluorouracil (5-FU), being characterized by a low molecular weight, 
rapidly leak from the APO cavity; thus to better stabilize the encapsulation, [82] proposed a 
simultaneous loading with gold nanoparticles (AU-NPs, 3nm of diameter) known for their 
optical and photothermal proprieties. 5-FU enters trough hydrophilic protein pores and once 
into the protein core binds AU-NPs via electrostatic interaction. This strategy avoided the 
leaking of 5-FU under physiological condition and promotes the drug release only after 
accumulation of APO inside the intracellular acidic compartments. In a very complete and 
worthy in vitro study, the complex was demonstrated to be able to increase the cytotoxic 
profile of the drug in different tumor cell lines, pointing out the wide applicability of the new 
therapeutic entities.  
Similarly, curcumin, a multi-target drug with potent antioxidant proprieties, was loaded into 
APO simultaneously with GD through an acidic dissociation protocol, obtaining about 9 and 
0.4 molecules of curcumin and GD respectively loaded into APO, with a consequent increase 
in APO diameter of about 66% (from 12 to 19 nm). In presence of curcumin, the gadolinium 
complex conserves its typical relaxivities and rapidly accumulates into liver (passive 
targeting). Based on this peculiar distribution, authors proposed the vector as a theranostic 
agent for a variety of liver diseases (Fig. 3) [83].  
 
4.4 A look over cancer, other possible applications of Apo as DDS 
The versatility of APO was recently exploited for the potentiality of antigen presentation onto 
the surface and immune stimulation in vaccines formulation. 
Generally, vaccines for immunization standard schedules are stably prepared and protocols of 
production are well standardized, but, for rapidly mutating-pathogens (as the influenza virus), 
it is necessary to prepare new complex vaccines on an annual basis to avoid possible 
circumvention of the immune system by mutated pathogen. 
The subunits of APO offer different regions tolerant to peptide insertion; these regions were 
therefore modified to obtain proteins expressing exogenous components that are able to 
conserve the ability to re-organize into spherical nanocage [84].  
Following this approach, APO was synthetized in a controlled manner in terms of quantity 
and location of substituent. By selecting the site for protein insertion, it is possible to expose 
the antigens on the outer surface [77-78] or both inner and outer [85]. From a technological 
point of view, new vaccines were characterized by using PCS ant TEM to prove spherical 
shape and presence of the exposed antigen.  
To evaluate the real efficacy of these new entities in comparison with licensed inactivated 
vaccines, different in vitro and in vivo tests were performed. Generally, after administration in 
mice, those APO exposing the antigen protein onto the outer surface induced a higher CD8+ 
and CD4+ T cell proliferative response and therefore their transformation in functional T cells 
[86].  
In view of expanding the applicability of APO in therapy, Zhang and coworkers exploited the 
applicability of APO in enzyme stabilization. Considering the large MW and steric hindrance 
of the molecule to be loaded, the internalization into the protein core appeared difficult, thus 
the enzyme glucose oxidase (GOx) (chosen as model enzyme) was immobilized onto the 
protein surface. Authors demonstrated that GOx linked on the surface through a biotin-
streptavidin approach retained most of its activity up to two weeks and resulted stable to 
exposition to high temperatures (up to 50°C). This study presents a novel approach to enhance 
stability and activity of enzyme with promising application in different therapy but also in 
biological assay [87]. 
Finally, in a recent paper aiming to explore the applicability of APO in brain disease therapy, 
H-Apo was tested on a cerebellar organotypic culture demonstrating high affinity for 
astrocyte cell and a rapid and massive accumulation into nuclei [50].  
 
Table 3: APO utilization in therapy 
5. Conclusion 
APO, featured by high stability, special and reproductive structure, auto-assembly ability and 
biocompatibility, is certainly one of the most investigated and interesting structures proposed 
in the modern scenario of nanomedicines.  
From the beginning of its history (less than 15 years) as material for drug delivery, its 
applicability was investigated within the field of cancer medicine due to its natural affinity for 
iron receptor, largely distributed on cells in rapid division. Unfortunately, based on its specific 
conformation and small internal spaces, only a limited number of chemotherapeutics (mainly 
belonging to anthracycline family as daunomycin and doxorubicin or contrast agent for tumor 
diagnoses and resulted suitable for successful loading into APO cage. Aiming to broaden the 
field of APO application, two main technological innovations were proposed: i) the 
engineering the protein surface by means of linkage of molecules able to drive the destiny of 
the protein cage; ii) the use of protein reactivity to link the drug or the active molecules 
directly on the surface. That way, APO became object of investigations in other fields of 
nanomedicine as gene therapy, immunology or liver pathology. 
 
6. Expert opinion 
Despite extensive promises, much work is needed before clinical translation of APO. As 
example, analyzing literature data, even if interestingly biological data are reported supporting 
the efficacy of this DDS, the study of the architecture and the structure of loaded APO are still 
at early stages. This situation, which represents the major limitation is translatability of APO 
to become DDS, is principally caused by unclear protocols for APO formulation and un-clear 
chemico-physical, morphological and technological characterization and it frequently 
generates conflicting outputs.  
Points to be focused with major attention are related to the nature and narrow size of APO 
complex and to the evidence that the analytical technique commonly used to characterize 
synthetic DDS as liposomes or nanoparticles (TEM, AFM, SEM, PCS, DSC etc) are unable to 
completely demonstrate structure, architecture and, in particular, the presence of drug or 
ligands onto APO surface. 
These data relating to chemico-physical and morphological characterization of APO 
formulations are essential to determine the fate and the perspective of any DDS, as any 
change in surface proprieties, even small differences in chains re-arrangements could strongly 
affect the interaction with serum proteins, recognition by immune systems, impacting on the 
cage biocompatibility and also on the ability to transport drug to the site of action.  
Currently, within their experimental plan only few studies are considering the evaluation of 
the effective recovery of conformation after the loading and disassembly process. Generally, 
when investigated, this issue on the final APO structure is approached by applying far-UV 
circular dichroism (CD). CD permits to evaluate the presence and the distribution of helical 
structures into the new protein entities. Despite these data are surely reliable, the results are 
not representative of the real integrity of protein after loading or disassembly/reassembly 
process.  
To overcome these limits, X-ray diffraction characterization, even if expensive and sometimes 
difficult to be rendered, could be considered as the best choice for the characterization of 
protein structural conformation. As an example, a study performed by SAXS technique 
showed clearly that protein reassembly process couldn’t be totally complete after strong 
acidification; under pH 2.4 the protein completely loses its spherical structure that cannot be 
recovered. The pH limit for pseudo-reversible restoration of the quaternary structure was set 
at 2.66 [28].  
One of the best example of an almost complete study of APO formulation is represented by a 
recent work [88] in which cisplatin loaded APO were formulated by applying the same 
method proposed by Ji and coworkers [47] and were submitted to a deep structural 
characterization by means of X-ray analyses and elaboration of data. By comparing loaded 
and unloaded samples with native APO, the authors confirmed that the overall structure 
(shape, polarity/hydrophobicity, volume and electrostatic potential of the surface) remained 
stable after the formulation process. Notably, comparing native and cisplatin-loaded APO, the 
most relevant structural differences were detected close to the site of drug loading and in 
particular at the His 132, found to be the metal-binding site.  
This work represents an important keystone for further investigations aiming to confirm the 
maintenance of the structural integrity of the protein, in particular regarding the encapsulation 
of non-metal drug with large MW.  
Furthermore, another point to be investigated aiming to improve the chances of translatability 
of APO as drug delivery systems is related to the drug release and in particular to the changes 
in morphology and architecture of APO cage during and after the release of the drugs. To our 
knowledge, poor information are given on this topic which obviously impacts on several 
technological key-features of APO drug delivery systems, as the efficiency in drug release, 
the possibility of governing/modifying the drug release and also the biocompatibility of APO 
after the release of the drugs. These aspects are still far from an overall evaluation and 
therefore need to be considered with a major interest. 
As final consideration, it seems almost clear that the improvement and the consecration of 
potentialities of APO application in different fields of drug targeting must be obtained by an 
extensive collaboration among researchers in the field of technology, chemical-physical 
characterization and physicians.  
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Fig 1: Graphical representation of the mechanisms for drug loading into APO. 
Fig 1: Graphical representation of the mechanisms for drug loading into APO. A) APO formed by H/L subunit can be passively loaded by 
simple incubation with a drug solution. In function of the MW of the drug, different loading dynamics could be supposed. B) APO structure 
can be broken down to subunits at low or high pH, incubated with drug and finally the structure can be reassembled once the pH is tuned 
back to neutral lead the drug molecules to be trapped into the protein inner core. 
 
  
 Fig.2: Schematic illustration of APO application in therapy. 
Fig.2: Schematic illustration of APO application in therapy. A) Different kind of active molecules were loaded of chemically linked on the 
surface of APO. These systems were applied for drug delivery and targeting, imaging and theranostic applications. B) Due to the intrinsic 
affinity for tumor cells loaded APO was mainly applied in cancer treatment, however recently this technology is applied in other field of 
research (immunotherapy, brain disease, enzyme replacement therapy).   
 
 
  
 Fig.3. Theranostic Applications: 
 
Figure 3. Theranostic Applications:  a) co-encapulation of active molecules (i.e. anticancer 5-FU, anti-oxidant curcumin) and contract agents 
(i.e. gold nanoparticles, Gd) into APO cage; b) encapsulation of anticancer molecule (i.e. doxorubicin) and surface engineering with multiple 
ligands for targeting and detection 
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VT: breast cancer 
cells (SKBR3 and 
MDA-MB-231). 
 
 
LSCM,FACS, 
MTT test 
Spherical cage of 12nm, 
stabilizing 10 molecules 
of drug.  
 
To solve: localization of 
the drug.  
VT: cellular 
internalization 
mediated by 
interaction with 
the TfR1 
receptor; 
selective 
antitumor 
activity in 
HER2 
overexpressing 
cells. 
[42
] 
Doxorubicin Pre-
complexation 
with Cu and 
incubation 
with intact 
APO 
RGD Recombinan
t  
(bacterial) 
AFM, DLS, gel 
filtration 
chromatography
, Fluorescence 
spectrometry  
 
VT: Human 
glioblstoma cell 
line (U87MG). 
CLFM, MTT test 
VV: WT and mice 
bearing U87MG 
cells. 
 
Pharmacokinetics
; tissue 
distribution; 
histology; tumor 
volume  
Cage of 18.7 nm with a 
loading efficiency of 
73%  
 
 
 
 
To solve: localization of 
the drug. 
VT: cellular 
internalization 
and 
cytotoxicity 
concentration 
dependent. 
VV: increased 
T(1/2) with 
respect to free 
drug.  
Accumulation 
into tumor 
tissue mediated 
[45
] 
by RGD-
integrin 
interaction.  
Tumor growth 
inhibition 
respect controls 
(APO Vs saline 
or free dug). 
Doxorubicin Disassembly 
in glycin 
buffer(pH 
2.5) followed 
by reassembly 
at 
physiological 
pH 
 Horse spleen gel 
electrophoreses, 
Fluorescence 
spectrometry 
 Drug loading of 23 
molecules of drug.  
 
To solve: structural 
conformation 
 [48
] 
Doxorubicin Disassembly 
at pH 2 
followed by 
reassembly at 
physiological 
pH 
 Recombinan
t (H-Human) 
UV-VIS, gel 
electrophoreses 
  
VT: human colon 
adenocarcinoma 
cell line (Caco-2), 
human liver 
carcinoma cell 
line (HepG2). 
 
LSCM and WB. 
 
 VT: Rapid 
cellular uptake 
and nuclear 
translocation of 
loaded APO  
 
 
[50
] 
Doxorubicin Disassembly 
at acidic pH 
followed by 
reassembly at 
physiological 
pH 
 Recombinan
t  
(H-Human) 
Fluorescence 
spectrometry 
 
 
VT: Hela cells 
and breast cancer 
cells (MDA 
MB468).  
 
 
 
Cage stabilizing 28 
molecules of drug; long 
term controlled of drug 
release (up to 72 h) in 
PBS pH 7. 
 
To solve: structural 
VT: Rapid 
cellular 
internalization 
and 
cytotoxicity 
(Apo Vs free 
dug)  
[51
] 
LSCM, MTT 
 
conformation   
 
 
 
Doxorubicin Disassembly 
in urea buffer 
followed by 
reassembly at 
physiological 
pH 
 Recombinan
t  
(bacterial) 
TEM, DLS, 
UV-VIS, 
HPLC-UV. 
 
  
 
VT: human colon 
cancer cell line 
(HT-29).  
CLFM.  
VV: mice bearing 
tumor cells (HT-
29 or A375 or 
MDA-MB-231). 
 
Pharmacokinetics
; tumor volume 
Spherical cage of 14nm, 
stabilizing 33 molecules 
of drug.  
pH-dependent drug 
release. 
 
 
 
To solve: structural 
conformation 
VT: cellular 
internalization 
and 
accumulation 
into lysosomes.  
 
VV: Increased 
plasma half-
life. 
Preferential 
accumulation 
in tumor tissue 
respect to 
healthy one. 
Tumor growth 
inhibition. 
(APO Vs free 
drug or Doxil) 
[52
] 
Doxorubicin 
Atropine 
Carbachol 
Disassembly 
in urea buffer 
followed by 
reassembly at 
physiological 
pH 
 Not reported TEM, DLS, 
UV-VIS, 
HPLC-UV 
 
VT: pancreatic 
cancer cells 
(PANC-1). 
LCSM. 
VV: WT and mice 
bearing PANC-1. 
 
Pharmacokinetics
; tumor volume  
Spherical cage of 11nm, 
stabilizing 33 (DOXO), 
47 (Atropine) or 58 
(Carbacol) molecules of 
drug.  
pH-dependent drug 
release. 
 
To solve: structural 
conformation 
VT : Rapid 
accumulation 
into tumoral 
cell through 
interaction with 
TfR1 receptors.  
 
VV: long term 
circulation. 
Accumulation 
[53
] 
into tumor site. 
Reduction of 
tumor volume 
and increased 
survival rate. 
(loaded APO 
Vs free drug) 
Daunomyci
n 
Pre-
complexation 
with PLLA. 
Disassembly 
at pH 5 
followed by 
reassembly at 
physiological 
pH 
 Not reported Fluorescence 
spectroscopy 
 Increased drug 
stabilization (4 times 
higher) respect to non 
complexed drug. 
 
To solve: chemical and 
structural 
characterization.  
 
 [24
] 
Daunomyci
n 
Pre-
complexation 
with PLLA. 
Disassembly 
at pH 5 
followed by 
reassembly at 
physiological 
pH 
HA Not reported TEM, UV-VIS- 
UV, FTIR, 
Fluorescence 
spectroscopy  
VT: Human lung 
carcinoma cell 
line (A549) and 
human lung 
fibroblast (MRC-
5).  
 
MTT, LCSM 
Spherical cage of 28 nm. 
pH dependent drug 
release. 
 
 
To solve: localization of 
the drug 
VT: Rapid 
accumulation 
into cancer cell 
expressing 
CD44 and 
cytotoxicity 
(APO Vs free 
drug). 
 
 
[56
] 
Cisplatin 
Carboplatin 
Oxaliplatin 
Disassembly 
at pH 2 
followed by 
reassembly at 
physiological 
pH 
 Not reported DLS, UV-VIS, 
CD, ICP-MS  
VT: rat 
pheochrocytoma 
cell line (PC12).  
 
 
 
Spherical cage of 13 nm 
encapsulating 45 
(cisplatin), 17 
(carboplatin), 23 
(oxaliplatin) molecule of 
drug.  
VT: Increased 
uptake and 
cytotoxicity of 
actives after 
loading 
(respect to free 
[35
] 
MTT, ICP-MS 
 
 
To solve: localization of 
the drug 
drug). 
 
 
Cisplatin 
Carboplatin 
Disassembly 
at pH 2 
followed by 
reassembly at 
physiological 
pH/Passive 
loading by pre 
incubation 
with Pt 
 Not reported TEM, UV-VIS, 
NMR, ICP-
AES, gel 
electrophoreses 
 
VT: rat 
pheochrocytoma 
cell line (PC12).  
 
 
MTT 
Cage encapsulating 15 of 
drug 
 
To solve: localization of 
the drug, structural 
characterization 
VT: Decreased 
viability of 
cancer cells 
(loaded Vs 
unloaded APO) 
 
 
[46
] 
Cisplatin Disassembly 
at pH 13 
followed by 
reassembly at 
physiological 
pH  
 Pig pancreas TEM, UV-VIS 
CD, ICP-MS.  
 
 
VT: gastric cancer 
cells (BGC823) 
and Hela. 
 
 
FACS, MALDI-
TOF/TOF, RT-
PCR. 
 
Spherical cage 
encapsulating 12 
Molecules of drug. 
 
 
To solve: localization of 
the drug 
VT: Induction 
of apoptosis.  
 
 
[47
] 
Cisplatin Disassembly 
at pH 2 
followed by 
reassembly at 
physiological 
pH 
Antibod
y direct 
to 
CSPG4 
Recombinan
t  
(H-bacterial) 
DLS, AUC, 
SEC 
VT: melanoma 
cell line 
(CSPG4+) and 
breast cancer cells 
(CSPG4-).  
Proliferation test 
 
VV: CD1 nude 
mice bearing 
tumor.  
 
Protein cage of 33 nm 
with a drug/protein 
molar ratio of 50 
 
 
 
 
 
 
To solve: localization of 
the drug, structural 
VT: increased 
antiproliferativ
e effect 
(modified Vs 
not modified 
APO). 
 
VV: reduction 
of tumor size in 
mice bearing 
melanoma. 
[57
] 
 
Evaluation of 
tumor size 
characterization and 
quantification of ligand 
siRNA 
(fluorescent 
model 
sequence) 
Incubation of 
modified 
APO with 
siRNA 
CAP and 
CTP  
Recombinan
t 
(H-Human) 
DLS, TEM, 
polyacrylamide 
gel 
VT: human breast 
cancer cells 
(MDA-MB-468) 
and vimentin 
expressing murine 
melanoma 
(B16F10). 
 
CLSM 
Complex of 53 nm 
stabilizing siRNA 
 
 
To solve: structural 
characterization 
VT: Rapid 
accumulation 
into cytoplasm 
of tumor cells  
[58
] 
 
Table 1: APO utilization in drug delivery to cancer 
 
LEGEND: AUC: analytical ultracentrifugation; CAP: Cationic peptides; CD: circular dichroism; CSPG4: Chondroitin sulfate proteoglycan 4; CTP: 
cell penetrating peptide; DLS: dynamic light scattering; FACS: fluorescence activated cells sorting; HA: Hyaluronic acid; HER2: Epidermal grown 
factor receptor 2; HPLC-UV: High-performance liquid chromatography- UV; ICP-EAS: Inductively coupled plasma atomic emission spectroscopy; 
ICP-MS: inductively coupled plasma mass spectrometer; LSCM: Laser-scanning Confocal Microscopy; MALDI TOF/TOF: Matrix-assisted laser 
desorption/ionization; MTT: 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolio; NMR: Nuclear magnetic resonance; PLLA: poly-L-aspartic acid; RGD: 
peptide with affinity for integrin receptor upregulated on tumor endothelial cells; RT-PCR: Reverse transcriptase-polymerase chain reaction; SEC: 
size exclusion chromatography; TEM: transmission electron microscopy; TfR1: transferrin receptor; UV-FTIR: Fourier transform infrared 
spectroscopy; UV-VIS: Ultraviolet–visible spectroscopy; WB: western blot. 
  
Drug 
Method of 
encapsulatio
n 
Surface 
modificatio
n 
Source of 
APO 
Outcomes/Short comings 
1.Chemico-
physical and 
technological 
studies 
2. In vitro (VT)/in 
vivo (VV) model  
 
test adopted 
Structural/technologic
al end point 
 
Focus to solve 
Biological end 
points 
RE
F 
Gadoliniu
m 
Passive 
loading 
 Not 
reported 
IR, TEM, UV-
Vis, ICP, SDS-
PAGE 
 Small cage stabilizing 
GD (III); increase GD 
longitudinal and 
transverse relaxivities 
 
To solve: structural 
characterization; 
localization of the drug. 
 [61] 
GD-
Me2DO2A 
Disassembly 
at pH 2 
followed by 
reassembly at 
physiological 
pH. Drug 
was added 
during the 
basification 
process. 
dextran Not 
reported 
TEM, UV-VIS, 
ICP-EAS 
VV: mice bearing 
HeLa cells.  
 
 
MRI, NIRF 
 
 
Spherical 30 nm 
modified cage 
encapsulating 36 
molecules of contrast 
agent.  
 
To solve: structural 
characterization; 
localization of the drug.
VV: massive 
accumulation in 
tumor site and 
high proton 
relaxivity. 
[60] 
GD-
HPDO3A 
Disassembly 
at pH 2 
followed by 
reassembly at 
physiological 
pH 
NCAM Not 
reported 
 VT:renal cell 
carcinoma cells 
(TEC). 
ICP-MS, MRI 
VV: SCID mice 
bearing TEC cells. 
 
MRI, histology, 
Modified cage 
encapsulating 8-10 
molecules of contrast 
agent whit high 
relaxivity (5 time 
higher respect to free 
molecule) 
 
VT: efficient 
cellular 
internalization 
(loaded/modifie
d APO Vs 
loaded APO) 
VV: 
accumulation 
[62] 
immunofluorescenc
e. 
 
To solve: structural 
characterization; 
localization of the drug.
into tumor site 
(modified/loade
d APO>loaded 
APO) 
GD-
HPDO3A 
Disassembly 
at pH 2 
followed by 
reassembly at 
physiological 
pH 
 Not 
reported 
  Cage encapsulating 10 
molecules of contrast 
agent. Relaxivity 
constant for several 
days. 
 
To solve: structural 
characterization; 
localization of the drug.
 [59] 
64Cu+Cy5 Dissociation 
at pH 2 
followed by 
reconstructio
n at 
physiological 
pH  
RGD4C Not 
reported 
DLS , TEM  VV: tumor bearing 
U87MG glioma. 
 
NIRF, PET, LCSM 
 
 
 
Absence of structural 
analyses and 
quantification of 
exposed ligands 
VV: massive 
tumor 
accumulation 
mediated by 
RGD-integrin 
interaction.  
[78] 
Fe3O4 Mineralizatio
n procedure 
None Recombina
nt (H-
Human) 
DLS, TEM, 
MR  
VT: murine 
macrophage cells.  
 
MR, ICP-MS 
Cage of 12-13 nm 
encapsulating 5000 Fe. 
 
To solve: structural 
characterization. 
VT: uptake of 
Apo into cells 
and 
accumulation 
of 116 ug 
Fe/cell within 
72 h 
[72] 
Fe3O4 Mineralizatio
n procedure 
RGD4G Recombina
nt (H-
Human) 
DLS, TEM, 
magnetic 
measurement 
VT: human 
melanoma cell line 
(C32).  
 
 
Spherical surface 
modified cage of 14 nm 
encapsulating 5000 
molecules of Fe 
VT: specific 
cellular uptake 
mediated by 
interaction with 
integrin. 
[73] 
FACS, TEM 
Fe3O4 Mineralizatio
n procedure 
RGD Recombina
nt  
(H-Human)  
 VT: bovine aortic 
endothelial cells. 
 
Fluorescence 
microscopy  
 
VV:WT mice. 
 
Fluorescence 
microscopy, 
histology 
 VT: Enhanced 
cellular uptake 
(modified vs 
not modified 
APO) 
VV: High 
accumulation in 
carotid arteries 
(modified vs 
not modified 
APO) 
[74] 
Fe3O4 Mineralizatio
n procedure 
EGF (ligand 
for EGFR) 
Recombina
nt  
(H-Human) 
DLS, TEM.  VT: breast 
epithelial cells 
(MCF-10A cells), 
breast cancer cells 
(MCF-7). 
 
FACS, MTT 
 
VV: nude mice 
bearing MDA.MB-
231 tumor cells. 
 
Weight and tumor 
size, fluorescence 
microscopy 
Spherical cage of 19 
nm  
 
 
 
 
 
To solve: structural 
characterization. 
VT: absence of 
toxicity at high 
APO 
concentration. 
Good targeting 
through cancer 
cell respect to 
normal cells 
(interaction 
with EGFR) 
VV: no 
influence in 
body weight 
and tumor size 
(modified/loade
d APO Vs 
saline). 
Accumulation 
into tumor 
tissue. 
[76] 
Mn Incubation 
with MnCl2 
at pH 9 
followed by 
reduction 
None Horse 
spleen 
TEM, UV-VIS, 
size exclusion 
chromatograph
y, NMR  
 Protein shell with a 
mineral core. 
Encapsulation of about 
1090 Mn atoms. 
 
To solve: structural 
characterization and 
localization of the 
contrast agent 
 [63] 
Mn Incubation 
with MnCl2 
at pH 9 
followed by 
reduction  
None Horse 
spleen and 
recombinan
t (H and L 
Human) 
TEM, UV-VIS, 
EDXA 
 Protein shell 
encapsulating mineral 
core 
 
To solve: structural 
characterization. 
 
 [64] 
Mn Incubation 
with MnCl2 
at pH 9 
followed by 
reduction 
None Horse 
spleen 
ICP-MS, 
Bradford 
quantification 
VT: HTC and 
hepatocytes 
 
ICP-MS 
VV: WT and HBV-
Tg mice  
 
Biodistribuition, 
MRI 
Protein structure 
encapsulating 3000 
Mn(II) ions  
 
To solve: structural 
conformation 
VT: high 
accumulation in 
healthy cells 
respect to 
hepatoma 
 
VV: detection 
of tumor lesion 
and improved 
sensitivity 
respect to 
commercial 
probe for MRI 
[65] 
Mn Incubation 
with MnCl2 
at pH 9 
None Not 
reported 
UV-VIS, NMR VT: melanogenic 
cells (B16-F10m) 
and non 
 VT: 
discrimination 
between 
[66] 
followed by 
reduction 
melanogenic cells 
(B16-F10non-m) 
UV-VIS; ICP-MS 
 
VV: mouse 
xenograft model 
bearing B16-F10m 
MR 
melanogenic 
and non 
melanogenic 
cells; high 
cellular uptake 
in melanogenic 
cells. 
 
VV: APO 
accumulation 
into tumor site 
 
Table 2: APO utilization in diagnosis 
LEGEND: EDXA: Energy Dispersive X-ray Analysis; LSCM: Laser-scanning Confocal Microscopy; ICP-MS: Inductively coupled plasma mass 
spectrometry; NMR: nuclear magnetic resonance; MR: magnetic resonance; NCAM: neural cell adhesion molecule; NIRF: near infrared 
fluorescence; PET: positron emission tomography; IR: Infrared spectroscopy; TEM: transmission electron microscopy; UV-VIS: Ultraviolet–visible 
spectroscopy; SDS-PAGE: Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis; ICP-EAS: Inductively coupled plasma atomic 
emission spectroscopy; DLS: : dynamic light scattering; MRI: Magnetic resonance imaging; ICP-MS: inductively coupled plasma mass 
spectrometer; PET: Positron Emission Tomography; MTT: 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolio; FACS: fluorescence activated cells 
sorting; RGD: Arginylglycylaspartic acid; EGF: Epidermal growth factor; 
 
 
 
 
  
Drug Method of encapsulation 
Surface 
modification
Source 
of APO 
Outcomes/Short comings 
1.Chemico-
physical and 
technological 
studies 
2. In vitro 
(VT)/in vivo 
(VV) model  
 
test adopted 
Structural/technological 
end point 
 
Focus to solve 
Biological end 
points 
REF 
Curcumin + 
Gd-
HPDO3A 
Disassembly 
at pH 2 
followed by 
reassembly at 
physiological 
pH.  
 Horse 
spleen 
SEC, UV-
VIS, ICP-MS 
VV: male mice 
(C57BL), mice 
model of liver 
injury. 
 
 
 
 
MR, histology  
Protein cage of 19 nm 
encapsulating 9.5 and 0.4 
molecules of curcumin 
and Gd-HPDO3A 
respectively. Ability to 
protect drug from 
degradation. 
 
To solve: structural 
characterization  
VV: preferential 
uptake by the liver 
(about 19% of 
injected dose).  
Reduction of ALT, 
leucocyte 
infiltration and 
hepatocyte 
apoptosis levels. 
(loaded Vs native 
APO). 
[83] 
AU-NP and 
5-FU 
Syntheses of 
AU-NPs 
inside the 
protein cage 
(AU 
reduction) 
followed by a 
passive 
loading of 5-
FU 
 Not 
reported
TEM, 
EDXA, 
PAGE, , CD, 
UV-VIS, 19F-
NMR. 
 
 
VT: non cancer 
cells (HKC); 
cancer cells 
(HeLa , HepG2, 
Caco-2, human 
hepatic L02). 
 
 
CCK-8, CLSM, 
TEM, ICP-MS, 
FACS, BrdU, 
WB 
Regular protein cage 
encapsulation 45 
molecules of drug. pH 
dependent drug release 
 
 
To solve: localization of 
the drug 
VT: Accumulation 
of APO into 
lysosomes; low 
toxicity in control 
cells; decreasing of 
IC50 value (15 
times Vs free drug) 
and increase of the 
antiproliferative 
effect in cancer 
cells. 
[84] 
Doxorubicin  Disassembly 
at pH 2 
Magnetic 
nanoparticles 
Not 
reported
Fluorimetric 
analysis, CE 
 Partial encapsulation of 
drug into protein cage 
 [54] 
followed by 
reassembly at 
physiological 
pH 
 and pH triggered drug 
release. 
 
To solve: structural 
characterization; 
localization of the drug 
Doxorubicin  Disassembly 
at pH 2 
followed by 
reassembly at 
physiological 
pH 
HWR 
peptide and 
anti PSMA 
antibodies; 
AU-NP 
Horse 
spleen 
DLS, FT-IR, 
PAGE, ICP-
MS 
VT: Human 
umbilical vein 
endothelial cells 
(HUVEC), 
human prostate 
adenocarcinoma 
cells (LNCCaP). 
 
FACS 
Complex protein cage of 
22 nm, pH dependent 
drug release. 
VT: specific 
uptake in tumoral 
cells and time 
dependent 
inhibition of cell 
growth. 
Excellent 
hemocompatibility.
[81]  
Table 3: APO utilization in theranostic applications 
LEGEND: AU-NPs: gold nanoparticles; BrdU: Bromodeoxyuridine; CCK-8:cell counting kit; CD= circular dichroism; CE: Capillary 
electrophoreses; CLSM: confocal laser scanning microscopy; DLS: dynamic light scattering; EDXA: energy dispersive X-ray analysis; FACS: 
fluorescence activated cells sorting; FACS: fluorescence activated cells sorting; FT-IR: Fourier transform infrared spectroscopy; ICP-MS: 
inductively coupled plasma mass spectrometer; MR: magnetic resonance; NMR: nuclear magnetic resonance; PMSA: prostate specific membrane 
antigen; SEC: size exclusion chromatography; TEM: transmission electron microscopy; UV-VIS: Ultraviolet–visible spectroscopy; WB: western 
blot: 5-FU: 5-Fluorouraciil. 
 
 
 
  
Drug Method of encapsulation 
Surface 
modification
Source of 
APO 
Outcomes/Short comings 
1.Chemico-
physical and 
technological 
studies  
2. In 
vitro/in 
vivo test 
Structural/technological 
end point 
Biological end points REF 
  
 
 
OT-1 and 
OT-2 
Recombinant
(bacterial) 
DLS, TEM, 
MS  
VT: 
splenocyte 
from 
C57BL/6 
mice. 
FACS. 
VV: 
C57BL/6 
mice. 
Cytokine 
assay 
Spherical cage of 13 nm 
exposing antigen in the 
inner or outer surface. 
 
To solve: structural 
characterization 
VT: increased of T cell 
proliferation after APO 
exposure. 
VV: effective 
differentiation of 
activated T cells in 
functional effector T 
cells 
[85] 
 Incubation of 
recombinant 
protein in 
TRIS buffer at 
physiologic 
pH and 
purification 
HA 
 
Recombinant 
(bacterial) 
DLS, TEM, 
SEC. 
VV: 
female 
BALB/c 
mice 
Smooth spherical cage 
exposing antigens 
 
To solve: structural 
characterization 
VV: inhibition of 
hemoagglutination  
[86] 
glucose 
oxidase 
Surface 
attachment 
through 
biotin-
streptavidin 
technology 
 Not reported TEM, UV-
VIS 
 Cage of 16 nm with an 
irregular morphology and 
largely aggregated 
stabilizing 8 molecules of 
enzyme. 
 
To solve: structural 
characterization 
 [50] 
 Table 4: APO utilization in therapy 
 
LEGEND: DLS: dynamic light scattering; FACS: fluorescence activated cells sorting; HA: Influenza virus hemagglutinin; MS: mass spectrometry; 
OT1/OT”: Antigen peptides derived from ovalbumin; SEC: size exclusion chromatography; TEM: transmission electron microscopy; UV-VIS: 
Ultraviolet–visible spectroscopy;
 
 Category Drug Note Ref 
Anticancer Tyrosine kinase 
inhibitor 
Gefinitinib 10 molecules/APO loading 42 
 Anthracyclin Doxorubicin -pre-complexation with Cu2+ 
increase the drug loading 
43-45 
Anthracyclin Daunorubicin -acidic protocol 
-surface conjugation for 
targeting 
-pre-complexation with 
negatively charged peptides 
22, 56 
Alkylating 
agents 
Cisplatin -strong acidic protocol 
-2 molecules/APO 
46 
Alkylating 
agents 
Carboplatin -strong acidic protocol 
-5 molecules/APO 
46 
Alkylating 
agents 
Cisplatin -alkaline protocol 47 
Alkylating 
agents 
Cisplatin -alkaline protocol 
-surface modification  
34,57 
Antimuscarinic Atropine / 53 
Cholinomimetic Carbachol / 53 
 SiRNA -modification with protamine-
derived peptides for 
complexation  
58 
 
Diagnostic Gadolinium -acidic protocol  
-neutral chelates 
59-62 
 Gadolinium -neutral chelates 
-surface modification for tumor 
targeting 
62 
Gadolinium - acidic dissociation 
-positively charged 
complexation 
60 
Magnetic 
Fe3O4 
-iron core formation 
 
72-73 
Magnetic 
Fe3O4 
-surface engineering for tumor 
targeting 
74-75 
Cu64  
Cy5 
-surface modification for tumor 
targeting 
78 
Mn   -alkaline protocol  
-accumulation in tumor 
63,64,65,66
 
Table 5: Summary of molecules and active agents loaded into APO nanocages. 
 
 
 
 
 
 
 
 
